Sorrento Therapeutics (SRNE) Earning Somewhat Favorable Media Coverage, Report Finds
Media stories about Sorrento Therapeutics (NASDAQ:SRNE) have been trending somewhat positive recently, Accern Sentiment Analysis reports. The research firm rates the sentiment of media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Sorrento Therapeutics earned a news sentiment score of 0.07 on Accern’s scale. Accern also assigned media headlines about the biopharmaceutical company an impact score of 45.3291843778142 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Here are some of the media headlines that may have effected Accern Sentiment’s rankings:
- Stocks Alert: ServiceMaster Global Holdings, Inc., (NYSE: SERV), Jones Lang LaSalle Incorporated, (NYSE: JLL … – Stocks In The News (press release) (tradingnewsnow.com)
- Hot Stock in Focus: Sorrento Therapeutics Inc (NASDAQ: SRNE) – Alpha Beta Stock (alphabetastock.com)
- Hot Stock’s Alert: Sorrento Therapeutics, Inc., (NASDAQ: SRNE), VWR Corporation, (NASDAQ: VWR), Meritor, Inc … – Stocks In The News (press release) (tradingnewsnow.com)
- ETFs with exposure to Sorrento Therapeutics, Inc. : November 2, 2017 (finance.yahoo.com)
- Sorrento Therapeutics (SRNE) versus Its Rivals Financial Survey (americanbankingnews.com)
Shares of Sorrento Therapeutics (NASDAQ SRNE) traded up $0.27 during midday trading on Monday, hitting $2.88. 1,048,565 shares of the stock were exchanged, compared to its average volume of 1,770,000. Sorrento Therapeutics has a 52-week low of $1.50 and a 52-week high of $6.60. The company has a quick ratio of 0.76, a current ratio of 0.76 and a debt-to-equity ratio of 0.28.
A number of equities research analysts have commented on the stock. HC Wainwright restated a “buy” rating and issued a $20.00 price target on shares of Sorrento Therapeutics in a report on Monday, September 18th. Oppenheimer Holdings, Inc. set a $7.00 price target on shares of Sorrento Therapeutics and gave the stock a “buy” rating in a report on Tuesday, August 29th. Roth Capital assumed coverage on shares of Sorrento Therapeutics in a report on Thursday, August 3rd. They issued a “buy” rating and a $7.00 price target for the company. Finally, UBS AG assumed coverage on shares of Sorrento Therapeutics in a report on Thursday, August 3rd. They issued an “outperform” rating and a $7.00 price target for the company. Six research analysts have rated the stock with a buy rating, The stock presently has a consensus rating of “Buy” and a consensus price target of $11.67.
ILLEGAL ACTIVITY WARNING: “Sorrento Therapeutics (SRNE) Earning Somewhat Favorable Media Coverage, Report Finds” was originally reported by Watch List News and is the property of of Watch List News. If you are accessing this news story on another website, it was illegally copied and republished in violation of US & international copyright & trademark law. The legal version of this news story can be read at https://www.watchlistnews.com/sorrento-therapeutics-srne-earning-somewhat-favorable-media-coverage-report-finds/1683512.html.
About Sorrento Therapeutics
Sorrento Therapeutics, Inc is a biopharmaceutical company. The Company is engaged in the discovery, acquisition, development and commercialization of drug therapeutics. Its primary therapeutic focus is oncology, including the treatment of chronic cancer pain. It is also developing therapeutic products for other indications, including immunology and infectious diseases.
Receive News & Ratings for Sorrento Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sorrento Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.